#KEYNOTE 355 TRIAL#

We thank the patients and investigators who have allowed us to evaluate innovative treatment approaches, anchored by KEYTRUDA, across multiple settings and stages of TNBC.' 'These new overall survival results confirm that KEYTRUDA in combination with chemotherapy represents an important treatment option for certain patients with metastatic TNBC. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. 'In the fight against triple-negative breast cancer, the subtype with the worst survival prognosis, new options that can extend the lives of patients are urgently needed,' said Dr. These OS results will be presented at an upcoming medical meeting and submitted to regulatory authorities. Findings from the final analysis show first-line treatment with KEYTRUDA in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine/carboplatin) demonstrated a statistically significant and clinically meaningful improvement in OS compared with chemotherapy alone in patients with mTNBC whose tumors expressed PD-L1 (Combined Positive Score ≥10).

#KEYNOTE 355 TRIAL#

KENILWORTH, N.J., July 27, 2021-( BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive overall survival (OS) results from the pivotal Phase 3 KEYNOTE-355 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC).

KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Show Statistically Significant OS for This Patient Population

Keynote 355